Compare NC & RZLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NC | RZLT |
|---|---|---|
| Founded | 1913 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Coal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 362.0M | 326.4M |
| IPO Year | 2006 | 2011 |
| Metric | NC | RZLT |
|---|---|---|
| Price | $49.60 | $3.29 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $9.67 |
| AVG Volume (30 Days) | 5.7K | ★ 1.4M |
| Earning Date | 05-05-2026 | 05-13-2026 |
| Dividend Yield | ★ 2.07% | N/A |
| EPS Growth | N/A | ★ 26.32 |
| EPS | ★ 2.35 | N/A |
| Revenue | ★ $104,778,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $20.45 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $32.80 | $1.07 |
| 52 Week High | $59.42 | $11.46 |
| Indicator | NC | RZLT |
|---|---|---|
| Relative Strength Index (RSI) | 49.76 | 51.51 |
| Support Level | $47.29 | $2.91 |
| Resistance Level | $51.09 | $3.73 |
| Average True Range (ATR) | 1.53 | 0.22 |
| MACD | 0.10 | -0.02 |
| Stochastic Oscillator | 62.23 | 44.70 |
NACCO Industries Inc is a holding company that operates in the mining and natural resource industries. It has three operating segments: Utility Coal Mining, Contract Mining, and Minerals and Royalties. The Utility Coal Mining segment, operated by North American Coal, manages surface coal mines that are exclusive, long-term fuel providers for power generation companies. The Contract Mining segment, operated by North American Mining, is a provider of a broad range of specialized, long-term contract mining services. The Minerals and Royalties segment, which includes the Catapult Mineral Partners (Catapult) business, acquires and promotes the development of mineral and royalty interests and other related investments.
Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.